Cargando…

Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?

BACKGROUND/AIMS: The measurement of infliximab trough levels (IFX-TLs) in patients with inflammatory bowel disease (IBD) is performed to optimize treatment. However, the association between the development of adverse events (AEs) and IFX-TLs has not been sufficiently studied thus far. To investigate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Theodoraki, Eirini, Orfanoudaki, Eleni, Foteinogiannopoulou, Kalliopi, Legaki, Evangelia, Gazouli, Maria, Koutroubakis, Ioannis E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Association for the Study of Intestinal Diseases 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566825/ https://www.ncbi.nlm.nih.gov/pubmed/32806874 http://dx.doi.org/10.5217/ir.2020.00042

Ejemplares similares

Recent Advances in the Optimization of Anti-TNF Treatment in Patients with Inflammatory Bowel Disease
por: Orfanoudaki, Eleni, et al.
Publicado: (2023)

Keeping on the High Quality of Health Care in Greek Inflammatory Bowel Disease Patients in the SARS-CoV-2 Era
por: Foteinogiannopoulou, Kalliopi, et al.
Publicado: (2020)

Use of vedolizumab in a patient with chronic and refractory pouchitis
por: Orfanoudaki, Eleni, et al.
Publicado: (2018)

Solid extraintestinal malignancies in patients with inflammatory bowel disease
por: Mala, Anastasia, et al.
Publicado: (2021)

Inflammatory bowel disease pathobiology: the role of the interferon signature
por: Andreou, Nicolaos-Panagiotis, et al.
Publicado: (2020)

Pyoderma gangrenosum associated with chronic refractory pouchitis: a case successfully treated with infliximab
por: Koumaki, Dimitra, et al.
Publicado: (2020)

Real-World Use and Adverse Events of SARS-CoV-2 Vaccination in Greek Patients with Inflammatory Bowel Disease
por: Orfanoudaki, Eleni, et al.
Publicado: (2022)

Tu1550: REAL WORLD USE AND ADVERSE EVENTS OF SARS-COV-2 VACCINATION IN GREEK PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Orfanoudaki, Eleni, et al.
Publicado: (2022)

Infliximab Trough Levels and Quality of Life in Patients with Inflammatory Bowel Disease in Maintenance Therapy
por: Parra, Rogério S., et al.
Publicado: (2018)

Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on Maintenance Treatment
por: Rolandsdotter, Helena, et al.
Publicado: (2017)

Serum trough levels of infliximab are not associated with peripheral arthralgia activity in patients with inflammatory bowel disease
por: Sekhri, Shaina, et al.
Publicado: (2021)

Association of Infliximab and Vedolizumab Trough Levels with Reported Rates of Adverse Events: A Cross-Sectional Study
por: Veisman, Ido, et al.
Publicado: (2021)

Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease
por: Choi, So Yoon, et al.
Publicado: (2017)

Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease
por: Choi, So Yoon, et al.
Publicado: (2019)

Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease
por: Oh, Eun Hye, et al.
Publicado: (2017)

Specific detection of OCT4 isoforms in inflammatory bowel disease
por: Maragkoudaki, Maria, et al.
Publicado: (2015)

High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study
por: Wilson, Aze, et al.
Publicado: (2021)

Crohn’s Disease-Like Features in a Patient With IgE and Selective IgG1 and IgG3 Deficiency
por: Drygiannakis, Ioannis, et al.
Publicado: (2023)

Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy
por: Cao, Wan-Ting, et al.
Publicado: (2022)

Colonic mucosal and serum expression of microRNAs in canine large intestinal inflammatory bowel disease
por: Konstantinidis, Alexandros Ο., et al.
Publicado: (2020)

Infliximab in inflammatory bowel disease
por: Papamichael, Konstantinos, et al.
Publicado: (2019)

Tu1549: IMPLEMENTATION AND SHORT-TERM ADVERSE EVENTS OF ANTI-SARSCOV-2 VACCINES IN INFLAMMATORY BOWEL DISEASE PATIENTS: AN INTERNATIONAL WEB-BASED SURVEY
por: Revés, Joana, et al.
Publicado: (2022)

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
por: Subedi, Smriti, et al.
Publicado: (2019)

Model Informed Precision Dosing Tool Forecasts Trough Infliximab and Associates with Disease Status and Tumor Necrosis Factor-Alpha Levels of Inflammatory Bowel Diseases
por: Primas, Christian, et al.
Publicado: (2022)

Lymphangiogenesis in Inflammatory Bowel Disease; A New Therapeutic Target?
por: Koutroubakis, Ioannis E, et al.
Publicado: (2016)

Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn’s Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab
por: Sorrentino, Dario, et al.
Publicado: (2015)

PB1909: A STUDY ON TROUGH LEVELS OF GENERIC DASATINIB AND ITS CORRELATION WITH ADVERSE EVENTS AND EFFICACY.
por: Nair, A., et al.
Publicado: (2022)

The Interplay between Mucosal Microbiota Composition and Host Gene-Expression is Linked with Infliximab Response in Inflammatory Bowel Diseases
por: Dovrolis, Nikolas, et al.
Publicado: (2020)

Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn’s Disease
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy
por: Huang, Vivian W., et al.
Publicado: (2015)

Inflammatory bowel disease of the lung: The role of infliximab?()
por: Hayek, Adam J., et al.
Publicado: (2015)

Association of miR-146 rs2910164, miR-196a rs11614913, miR-221 rs113054794 and miR-224 rs188519172 polymorphisms with anti-TNF treatment response in a Greek population with Crohn’s disease
por: Papaconstantinou, Ioannis, et al.
Publicado: (2017)

Risk factors for gastroesophageal reflux disease and analysis of genetic contributors
por: Argyrou, Alexandra, et al.
Publicado: (2018)

Polymorphisms of the BARX1 and ADAMTS17 Locus Genes in Individuals With Gastroesophageal Reflux Disease
por: Argyrou, Alexandra, et al.
Publicado: (2019)

Osteoclast: like giant cell undiferrentiated pancreatic tumor diagnosed by means of EUS guided FNA
por: Kalogeraki, Alexandra, et al.
Publicado: (2021)

Treatment of acute severe ulcerative colitis using accelerated infliximab regimen based on infliximab trough level: A case report
por: Garate, Ana Lorena Sousa de Vasconcelos, et al.
Publicado: (2021)

Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn’s disease
por: Choi, So Yoon, et al.
Publicado: (2023)

Predictors of Adverse Events and Determinants of the Voriconazole Trough Concentration in Kidney Transplantation Recipients
por: Zhao, Yi‐Chang, et al.
Publicado: (2020)

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
por: van der Maas, Aatke, et al.
Publicado: (2012)

Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease
por: Vaughn, Byron P., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hrnfcdessk5hjirl2j2rok7te9